Create a narrative

Allurion Technologies Community

NYSE:ALUR Community

1 Narratives written by author
0 Comments on narratives written by author
7 Fair Values set on narratives written by author

Create a narrative

Allurion Technologies

AN

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Low-dose GLP-1 Combo And FDA Approval Will Expand Obesity Care

Key Takeaways The combination therapy approach and clinical advancements are set to drive increased revenue and expand market share in obesity and related treatments. Restructuring efforts and strategic plans, including a move to B2B2C models, aim to boost efficiency, margins, and earnings moving forward.

US$10.63

FV

78.1% undervalued

15.87%

Revenue growth p.a.

0

0

7

Updated